

# Respiri

Fund raise

## Raise anticipated to fund the Access acquisition

Following the proposed acquisition of Access Managed Services in May 2023, Respiri announced that it has raised the A\$3m as planned as part of the share purchase plan (SPP), which we believe are the funds needed to close the acquisition (10 August scheduled closing date). The company has raised a total of A\$4.35m (including a convertible note with Obsidian Global) to cover the upfront payment (US\$1.25m) for the acquisition, working capital to accelerate US commercialisation and the US\$0.25m acquisition purchase consideration due three months post-close. Also, in Q423 (ending June 2023), Respiri signed three new remote patient monitoring (RPM) agreements, increasing the total contracted healthcare customers to 13 (across eight US states), while also bolstering its sales pipeline. The acquisition of the Access platform is a key component of management's commercialization strategy and we anticipate Respiri to be on track to reach break-even in mid-CY24.

Year end	Revenue (A\$m)	EBITDA* (A\$m)	PBT* (A\$m)	EPS* (p)	P/revenue (x)	P/E (%)
06/21	1.4	(8.4)	(8.5)	(1.22)	25.2	N/A
06/22	0.8	(6.2)	(6.3)	(0.87)	46.8	N/A
06/23e	1.7	(4.2)	(4.2)	(0.51)	21.1	N/A
06/24e	5.9	(1.1)	(1.1)	(0.13)	6.2	N/A

Note: \*EBITDA, PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments. FY24e EPS figures do not reflect shares to be issued as part of the Q3 CY23 SPP.

With the successful SPP fund raise of A\$3m, Respiri has met one of the primary conditions for the Access acquisition (ie raising US\$2.5m in funding). Respiri raised A\$2.4m via the SPP offer and A\$0.6m in a shortfall placement. As per the initial SPP, eligible shareholders could subscribe up to 88.2m shares at the offer price of A\$0.034 per share, along with one free attached option for every two shares subscribed, to raise maximum A\$3m in gross proceeds. The share option is exercisable at A\$0.065/share until 30 June 2025. Additionally, the company issued an SPP shortfall offer for non-shareholders (at the board's discretion) to cover for shortfall securities on similar terms to the SPP. We estimate c 80% of eligible shareholders took part in the initial SPP. Respiri also entered into convertible note agreement with Obsidian Global to raise another A\$1.35m, where notes are fully convertible into shares with one free option for four shares issued on conversion. More details on the Access deal and potential benefits are covered in our [prior note](#).

In its recently released [Q423 cash flow report](#), Respiri reported operational highlights during the quarter, including ongoing progress in wheezo commercialization, with the signing of three additional RPM agreements (US), the appointment of a chief commercial officer in the US and the implementation of AI capabilities in its operations. Additionally, in July the company entered into a three-year distribution and marketing agreement (non-exclusive) with [Fi-Med Management](#), to expand its distribution network across large healthcare organisations. Some of the important business leads during the quarter included two large US-based insurers (which may be finalised in Q124), a healthcare provider with a national presence (about 0.5m patient pa) and a California-based accountable care organization. The company closed Q423 with a cash balance of A\$0.146m excluding the A\$4.34m fund raise. We will present our revised estimates and valuation following the deal closure.

### Healthcare equipment

14 August 2023

Price **A\$0.04**

Market cap **A\$35m**

US\$0.65/A\$

Cash balance (A\$m) at end-June 2023 (excluding SPP fund raise in August 2023) 0.15

Shares in issue (excluding shares issued as part of Q3 CY23 SPP) 860.7m

Free float 79.6%

Codes RSF, RSUF

Primary exchange ASX

Secondary exchange OTCQB

### Share price performance



### Business description

Respiri is an Australian-based medical device and SaaS company focused on respiratory health management through its integrated wheezo platform. The device is a breath sensor that works with the Respiri mobile applications to record data such as wheeze rates, breath recordings and other environmental factors and medication usage, which can be accessed by physicians in real time. wheezo received FDA clearance in March 2021 and launched in the US in December 2021. In May 2023, Respiri announced the acquisition of US RPM partner Access, which, after deal closure, will make it one of the few RPM companies with its own IP (wheezo).

### Analysts

Soo Romanoff +44 (0)20 3077 5700

Nidhi Singh +44 (0)20 3077 5700

[healthcare@edisongroup.com](mailto:healthcare@edisongroup.com)

[Edison profile page](#)

**Respiri is a research client of Edison Investment Research Limited**

---

## General disclaimer and copyright

This report has been commissioned by Respire and prepared and issued by Edison, in consideration of a fee payable by Respire. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

**Accuracy of content:** All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

**Exclusion of Liability:** To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out of or in connection with the access to, use of or reliance on any information contained on this note.

**No personalised advice:** The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

**Investment in securities mentioned:** Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2023 Edison Investment Research Limited (Edison).

---

## Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

---

## New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

---

## United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

---

## United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

---